Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Announce Data Required for Conditional Early Approval
July 12, 2017
- Further Transformation beyond Pricing Overhaul Inevitable: Outgoing MHLW Economic Affairs Chief
July 10, 2017
- Applications for Partial Modification to Suffice to Change Manufacturing Processes for Biopharmaceuticals: MHLW Notification
July 7, 2017
- MHLW to Enhance Awareness about Tougher Controls on Private Importing of Drugs by Doctors
July 7, 2017
- MHLW Floats Standard Processing Time for Cost-Effective Assessments: Chuikyo
July 6, 2017
- Chuikyo Reps Trade Barbs over Timing of Post-“CEA” Price Adjustments
July 6, 2017
- Drugs Containing Codeine to Be Contraindicated in Children Younger than 12: MHLW Notifications
July 6, 2017
- Suzuki Tapped for Newly Created Medical Commissioner Post: MHLW Personnel Reshuffle
July 5, 2017
- Add Sclerosing Cholangitis to ADR List in Opdivo Label: MHLW
July 5, 2017
- MHLW OKs Spinraza, Tenelia-Canaglu Combo, and More
July 4, 2017
- MHLW Calls for Surprise Inspection for API Makers
July 3, 2017
- Revised GPSP Ministerial Ordinance Will Establish“Post-Marketing Database Surveys”: MHLW
July 3, 2017
- MHLW to Provide Administrative Guidance in 23 Cases of Ethical Drug Advertising Activities
July 3, 2017
- MHLW to Soon Present Criteria for Drugs Subject to Optimal Use Guidelines
June 30, 2017
- MHLW Issues Notification to Redefine “Three Officer System” at Drug Makers
June 29, 2017
- Yamamoto Chemical Slapped with 22-Day Biz Suspension
June 29, 2017
- JMA’s Nakagawa Wants Clear Definitions for Original Drug, LLP, AG, Gx: Chuikyo
June 29, 2017
- “CEA” Scheme to Be Initially Introduced for Post-Listing Price Adjustment, Targeting Innovative Products with Big Market: Chuikyo
June 29, 2017
- Chuikyo Agrees to “Reward Innovation More” when Using Cost Calculation Pricing Method
June 29, 2017
- PMDA’s Review-Related Ordinary Loss Nearly Doubled in FY2016
June 28, 2017
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…